The genetic risk of disease, not remission status, determines overall survival of patients with high-risk acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Furthermore, there is no benefit of remission induction with standard salvage chemotherapy prior to allo-HSCT. These are the results of a recently published long-term follow-up [1] of the ASAP trial [2], which was conducted at renowned universities and clinics across Germany. This clinical trial was financed and organized by the international non-profit organization DKMS, which is dedicated to fighting blood cancer and committed to advancing research in in hematological diseases.